+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Chronic Idiopathic Constipation Therapeutic Market - Global Forecast 2026-2032- Product Image
Chronic Idiopathic Constipation Therapeutic Market - Global Forecast 2026-2032- Product Image
New

Chronic Idiopathic Constipation Therapeutic Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 194 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6010861
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The chronic idiopathic constipation therapeutic market is experiencing notable transformation, propelled by shifts in clinical practice, patient engagement, and evolving commercial dynamics. Senior leaders must adapt strategies that address not only product innovation, but also real-world operational and payer challenges in this high-impact segment.

Market Snapshot: Chronic Idiopathic Constipation Therapeutic Market

The Chronic Idiopathic Constipation Therapeutic Market expanded from USD 1.37 billion in 2025 to USD 1.48 billion in 2026, with a projected CAGR of 7.93% through 2032. The market is expected to reach USD 2.35 billion by the end of this period, underscoring strong demand across global regions and a dynamic therapeutic landscape that continues to evolve in both scale and complexity. Senior decision-makers confront an increasingly competitive environment shaped by shifts in clinical standards, payer priorities, and innovative technology, setting the stage for robust growth and expanding commercial opportunities.

Scope & Segmentation

  • Drug Classes: 5-HT4 receptor agonists, chloride channel activators, guanylate cyclase-C agonists, osmotic laxatives, stimulant laxatives, and stool softeners address diverse therapeutic requirements within the chronic idiopathic constipation therapeutic market.
  • Routes of Administration: Oral therapies and rectal interventions enable tailored delivery based on clinical need and patient preference.
  • Prescription Status: Over-the-counter and prescription therapies expand access for patients with varying clinical profiles and support differentiated go-to-market models.
  • Treatment Modalities: Pharmacological and non-pharmacological options, including supportive adjuncts, facilitate integrated, patient-centered approaches. This enables payers and providers to match solutions to specific patient populations and disease severities.
  • Distribution Channels: Hospital, online, and retail pharmacies enhance value chain diversification and adaptation to changing patterns of patient engagement and medication delivery.
  • Regions Covered: Americas, Europe, Middle East & Africa, and Asia-Pacific present unique regulatory, payer, and commercial environments. Each region requires nuanced segmentation and localization strategies for optimal growth.

Today’s market relies heavily on technology for digital health solutions and remote monitoring. These innovations are driving improvements in adherence, outcome measurement, and patient connectivity. The regulatory landscape, reimbursement requirements, and commercial access protocols vary across regions, reinforcing the necessity for senior leadership to leverage granular segmentation in growth planning.

Key Takeaways

  • Balancing clinical efficacy, tolerability, and patient preferences remains essential as regulatory and payer criteria become more sophisticated, requiring comprehensive alignment in strategy.
  • The therapeutic model is transitioning toward mechanism-driven therapies, aiming to restore physiological motility and address patient variation, signaling a move beyond symptom-only management.
  • Integrated digital platforms and delivery models address treatment inertia, supporting longer-term outcomes by facilitating better engagement and adherence tracking among patient populations.
  • Commercial strategies increasingly emphasize product convenience and proven benefit to influence prescriber and payer decisions, which can shape adoption rates and sustain market share.
  • Patient-reported outcomes and real-world adherence data are critical in shaping value assessments and in building the case for therapies with long-term durability and relevance in everyday care.
  • Collaboration among biopharma companies, digital health innovators, diagnostics providers, and distribution partners is pivotal for enhancing access, enabling differentiated value propositions, and responding to the evolving needs within the chronic idiopathic constipation landscape.

Tariff Impact: United States Tariff Adjustments in 2025

Recent United States tariff changes are impacting global pharmaceutical supply chains, increasing organizational focus on proactive sourcing strategies and risk mitigation for essential therapeutic inputs. Companies now consider nearshoring, supplier diversification, and carefully structured contracts to safeguard stability, competitiveness, and continuity of supply. This environment prioritizes agile operational models and contingency planning as foundational to maintaining pricing power, negotiating favorable terms, and ensuring continued patient access via robust distribution networks. Consequently, stakeholders continually adapt their supply chain frameworks to uphold both service standards and financial performance amid market volatility.

Methodology & Data Sources

This analysis uses a mixed-methods approach, synthesizing expert interviews with gastroenterology professionals, pharmacy leaders, and payer representatives. Clinical trial registries, real-world utility data, regulatory submissions, and de-identified claims further validate the findings, supporting robust, evidence-based recommendations for strategic decision-making.

Why This Report Matters

  • Supports swift identification of therapeutics and business models that are best suited to emerging provider, payer, and patient expectations in the chronic idiopathic constipation therapeutic market.
  • Informs clear, targeted investment and portfolio strategies by highlighting the impact of segmentation, regional differences, and distribution channel optimization.
  • Connects operational, clinical, and commercial insights, enabling leaders to benchmark outcomes and secure measurable patient and business impacts in a rapidly evolving landscape.

Conclusion

This report equips senior leaders to coordinate clinical, operational, and payer strategies for sustained commercial and patient value. Leveraging mechanism-driven innovation, partnership models, and robust supply chains ensures continued relevance and growth in a competitive market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Chronic Idiopathic Constipation Therapeutic Market, by Treatment Modality
8.1. Non-Pharmacological / Adjunct
8.2. Pharmacological
9. Chronic Idiopathic Constipation Therapeutic Market, by Drug Class
9.1. Guanylate Cyclase-C (GC-C) Agonists
9.2. Osmotic Laxatives
9.3. Stimulant Laxatives
9.4. Serotonin 5-HT4 Receptor Agonists
9.5. Bulking Agents
9.6. Stool Softeners
10. Chronic Idiopathic Constipation Therapeutic Market, by Formulation Type
10.1. Solid Oral Formulations
10.1.1. Tablets
10.1.2. Capsules
10.2. Liquid Oral Formulations
10.2.1. Solutions
10.2.2. Suspensions
10.3. Rectal Formulations
10.3.1. Suppositories
10.3.2. Enemas
11. Chronic Idiopathic Constipation Therapeutic Market, by Route Of Administration
11.1. Rectal
11.2. Oral
12. Chronic Idiopathic Constipation Therapeutic Market, by Prescription Status
12.1. Over-the-Counter (OTC) Medicines
12.2. Prescription Medicines
13. Chronic Idiopathic Constipation Therapeutic Market, by End User
13.1. Hospitals
13.2. Specialty Gastroenterology Clinics
13.3. Primary Care Clinics
13.4. Home Care Settings
13.5. Long Term Care Facilities
13.6. Rehabilitation Centers
14. Chronic Idiopathic Constipation Therapeutic Market, by Distribution Channel
14.1. Hospital Pharmacies
14.2. Online Pharmacies
14.3. Retail Pharmacies
15. Chronic Idiopathic Constipation Therapeutic Market, by Age Group
15.1. Pediatric Patients
15.2. Adult Patients
16. Chronic Idiopathic Constipation Therapeutic Market, by Region
16.1. Americas
16.1.1. North America
16.1.2. Latin America
16.2. Europe, Middle East & Africa
16.2.1. Europe
16.2.2. Middle East
16.2.3. Africa
16.3. Asia-Pacific
17. Chronic Idiopathic Constipation Therapeutic Market, by Group
17.1. ASEAN
17.2. GCC
17.3. European Union
17.4. BRICS
17.5. G7
17.6. NATO
18. Chronic Idiopathic Constipation Therapeutic Market, by Country
18.1. United States
18.2. Canada
18.3. Mexico
18.4. Brazil
18.5. United Kingdom
18.6. Germany
18.7. France
18.8. Russia
18.9. Italy
18.10. Spain
18.11. China
18.12. India
18.13. Japan
18.14. Australia
18.15. South Korea
19. United States Chronic Idiopathic Constipation Therapeutic Market
20. China Chronic Idiopathic Constipation Therapeutic Market
21. Competitive Landscape
21.1. Market Concentration Analysis, 2025
21.1.1. Concentration Ratio (CR)
21.1.2. Herfindahl Hirschman Index (HHI)
21.2. Recent Developments & Impact Analysis, 2025
21.3. Product Portfolio Analysis, 2025
21.4. Benchmarking Analysis, 2025
21.5. AbbVie Inc.
21.6. Albireo Pharma, Inc. by Ipsen S.A.
21.7. ANI Pharmaceuticals, Inc.
21.8. Ardelyx Inc.
21.9. Bausch Health Companies Inc.
21.10. Bayer AG
21.11. Dr. Reddy’s Laboratories Ltd.
21.12. Eisai Co., Ltd.
21.13. Ferring B.V.
21.14. Ironwood Pharmaceuticals, Inc.
21.15. Lupin Limited
21.16. Mallinckrodt plc
21.17. MSN Laboratories Private Limited
21.18. Norgine B.V.
21.19. Sanofi S.A.
21.20. Shionogi & Co., Ltd.
21.21. Takeda Pharmaceutical Company Limited
21.22. Zydus Cadila Limited
List of Figures
FIGURE 1. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 15. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 16. CHINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY NON-PHARMACOLOGICAL / ADJUNCT, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY NON-PHARMACOLOGICAL / ADJUNCT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY NON-PHARMACOLOGICAL / ADJUNCT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PHARMACOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PHARMACOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY GUANYLATE CYCLASE-C (GC-C) AGONISTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY GUANYLATE CYCLASE-C (GC-C) AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY GUANYLATE CYCLASE-C (GC-C) AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OSMOTIC LAXATIVES, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OSMOTIC LAXATIVES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OSMOTIC LAXATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STIMULANT LAXATIVES, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STIMULANT LAXATIVES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STIMULANT LAXATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SEROTONIN 5-HT4 RECEPTOR AGONISTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SEROTONIN 5-HT4 RECEPTOR AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SEROTONIN 5-HT4 RECEPTOR AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY BULKING AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY BULKING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY BULKING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STOOL SOFTENERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STOOL SOFTENERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STOOL SOFTENERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SUPPOSITORIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SUPPOSITORIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SUPPOSITORIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ENEMAS, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ENEMAS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ENEMAS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OVER-THE-COUNTER (OTC) MEDICINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OVER-THE-COUNTER (OTC) MEDICINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OVER-THE-COUNTER (OTC) MEDICINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION MEDICINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION MEDICINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION MEDICINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SPECIALTY GASTROENTEROLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SPECIALTY GASTROENTEROLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SPECIALTY GASTROENTEROLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRIMARY CARE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRIMARY CARE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LONG TERM CARE FACILITIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LONG TERM CARE FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LONG TERM CARE FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY REHABILITATION CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY REHABILITATION CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 110. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 111. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 112. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 113. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 114. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 115. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 116. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 117. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 118. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
TABLE 119. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 120. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 121. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 122. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 124. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 125. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 126. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 127. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 128. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 129. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 130. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
TABLE 131. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 132. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 133. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 134. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 135. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 136. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 137. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 138. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 139. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 140. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 141. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 142. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
TABLE 143. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 144. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 145. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 158. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 159. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 160. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 161. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 162. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 163. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 164. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 165. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 166. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
TABLE 167. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 168. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 169. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 170. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 171. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 172. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 173. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 174. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 175. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 176. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 177. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 178. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
TABLE 179. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 180. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 181. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 182. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 183. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 184. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 185. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 186. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 187. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 188. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 189. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 190. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
TABLE 191. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 192. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 193. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 194. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 195. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 196. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 197. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 198. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 199. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 200. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 201. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 202. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
TABLE 203. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 204. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 205. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 206. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 207. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 208. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 209. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 210. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 211. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 212. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 213. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 214. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 215. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
TABLE 216. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 217. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 218. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 219. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 220. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 221. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 222. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 223. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 224. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 225. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 226. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 227. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
TABLE 228. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 229. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 230. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 231. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 232. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 233. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 234. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 235. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 236. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 237. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 238. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 239. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
TABLE 240. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 241. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 242. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 243. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 244. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 245. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 246. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 247. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 248. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 249. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
TABLE 250. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 251. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
TABLE 252. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 253. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 254. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 255. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 256. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 257. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 258. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 259. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPE

Companies Mentioned

The key companies profiled in this Chronic Idiopathic Constipation Therapeutic market report include:
  • AbbVie Inc.
  • Albireo Pharma, Inc. by Ipsen S.A.
  • ANI Pharmaceuticals, Inc.
  • Ardelyx Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Dr. Reddy’s Laboratories Ltd.
  • Eisai Co., Ltd.
  • Ferring B.V.
  • Ironwood Pharmaceuticals, Inc.
  • Lupin Limited
  • Mallinckrodt plc
  • MSN Laboratories Private Limited
  • Norgine B.V.
  • Sanofi S.A.
  • Shionogi & Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Zydus Cadila Limited

Table Information

Report AttributeDetails
No. of Pages194
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.48 Billion
Forecasted Market Value ( USD ) by 2032 $ 2.35 Billion
Compound Annual Growth Rate7.9%
Regions CoveredGlobal
No. of Companies Mentioned18

Related Topics

Related Reports

Chronic Idiopathic Constipation Therapeutic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Chronic Idiopathic Constipation Therapeutic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 180 Pages
  • Global
From
Chronic Idiopathic Constipation - Market Insights, Epidemiology, and Market Forecast - 2034 - Product Image

Chronic Idiopathic Constipation - Market Insights, Epidemiology, and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Chronic Idiopathic Constipation (CIC) Epidemiology Forecast 2025-2034 - Product Image

Chronic Idiopathic Constipation (CIC) Epidemiology Forecast 2025-2034

  • Report
  • 150 Pages
  • Global
From
Constipation Treatment Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Constipation Treatment Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Constipation Treatment - Global Strategic Business Report - Product Image

Constipation Treatment - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From

About the Chronic Idiopathic Constipation Drugs Market

Within the realm of gastrointestinal drugs, a distinct segment is dedicated to the treatment of Chronic Idiopathic Constipation (CIC), a prevalent condition characterized by infrequent bowel movements, difficulty in stool passage, or a sense of incomplete evacuation without an identifiable cause. The market for CIC medications includes a range of therapeutic options that aim to alleviate symptoms and improve patients' quality of life. These pharmacologic treatments largely consist of laxatives, stool softeners, prokinetic agents, chloride channel activators, guanylate cyclase-C agonists, and serotonin 5-HT4 receptor agonists, each targeting different aspects of the complex gastrointestinal function to induce bowel movements or enhance stool consistency. Development in this sector is driven by a combination of factors, including advancing understanding of gut motility and the nervous system, patient need, and innovation in drug design and delivery mechanisms. Several companies have established prominence in the Chronic Idiopathic Constipation Drugs market through the development and commercialization of effective treatments. Leading this niche are pharmaceutical firms such as Ironwood Pharmaceuticals, Takeda Pharmaceutical Company, Synergy Pharmaceuticals, Ardelyx, Pfizer, and Allergan. These companies offer a diverse portfolio of products and continue to invest in research and development to improve therapeutic outcomes and address unmet medical needs within the discipline of gastrointestinal health. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.